Kennedy Capital Management Inc. acquired a new position in FibroGen Inc (NASDAQ:FGEN) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 59,816 shares of the biopharmaceutical company’s stock, valued at approximately $2,835,000. Kennedy Capital Management Inc. owned about 0.07% of FibroGen as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also recently made changes to their positions in FGEN. Eagle Asset Management Inc. purchased a new position in FibroGen in the 3rd quarter worth approximately $46,158,000. First Trust Advisors LP raised its holdings in FibroGen by 1,058.4% in the 4th quarter. First Trust Advisors LP now owns 776,640 shares of the biopharmaceutical company’s stock worth $36,813,000 after acquiring an additional 709,598 shares during the last quarter. Carillon Tower Advisers Inc. purchased a new position in FibroGen in the 4th quarter worth approximately $282,486,000. BlackRock Inc. raised its holdings in FibroGen by 4.0% in the 4th quarter. BlackRock Inc. now owns 6,326,075 shares of the biopharmaceutical company’s stock worth $299,855,000 after acquiring an additional 244,617 shares during the last quarter. Finally, Jennison Associates LLC purchased a new position in FibroGen in the 3rd quarter worth approximately $12,105,000. Institutional investors own 61.39% of the company’s stock.
Shares of FibroGen Inc (FGEN) opened at $53.45 on Wednesday. The firm has a market cap of $4,530.15, a price-to-earnings ratio of -30.20 and a beta of 1.76. The company has a debt-to-equity ratio of 0.17, a quick ratio of 9.70 and a current ratio of 9.70. FibroGen Inc has a 12 month low of $22.75 and a 12 month high of $63.00.
In other news, insider K Peony Yu sold 2,851 shares of the company’s stock in a transaction on Thursday, December 14th. The stock was sold at an average price of $43.70, for a total value of $124,588.70. Following the completion of the sale, the insider now directly owns 162,086 shares in the company, valued at approximately $7,083,158.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Pat Cotroneo sold 49,500 shares of the company’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of $55.96, for a total value of $2,770,020.00. Following the completion of the sale, the vice president now owns 207,392 shares of the company’s stock, valued at $11,605,656.32. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 448,237 shares of company stock valued at $23,351,636. Company insiders own 13.60% of the company’s stock.
WARNING: “59,816 Shares in FibroGen Inc (FGEN) Purchased by Kennedy Capital Management Inc.” was originally published by American Banking News and is the property of of American Banking News. If you are viewing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this story can be accessed at https://www.americanbankingnews.com/2018/03/14/59816-shares-in-fibrogen-inc-fgen-purchased-by-kennedy-capital-management-inc.html.
FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.
Want to see what other hedge funds are holding FGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for FibroGen Inc (NASDAQ:FGEN).
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.